A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Active, not recruiting · Phase 2 · NCT05952037
Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 16
- Sites paid
- 15
- Planned or actual enrollment
- 114
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Sonrotoclax (drug), Zanubrutinib (drug)
- Dates
- Started 2023-10-23; completion 2028-08
- Results posted
- Not yet
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $1.0M in research payments for this study in 2025 (110 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Geoffrey Shouse, D.O., PH.D. Hematology · Duarte, CA
- Ira Smalberg, MD Radiology · Santa Monica, CA
- Kimberley Doucette, M.D. Medical Oncology · Washington, DC
- Georgios Pongas, M.D Hematology & Oncology · Miami, FL
- Shuo Ma, M.D., PH.D. Hematology & Oncology · Chicago, IL
- Mark Tann, M.D. Nuclear Medicine · Indianapolis, IN
- Vikram A. Sahni, M.D. Radiology · Wellesley, MA
- Steven P. Treon, MD, PHD Specialist · Boston, MA
- Ashraf Z. Badros, M.D. Medical Oncology · Baltimore, MD
- Prashant Kapoor, MD Hematology · Rochester, MN
- Shebli Atrash, MD Hematology & Oncology · Charlotte, NC
- Maria L. Palomba, MD Hematology & Oncology · New York, NY
- Larry D. Anderson JR., M.D. , PHD Medical Oncology · Dallas, TX
- Amandeep Godara, MD Hematology & Oncology · Salt Lake City, UT
- Bruce O. Hough, MD Hematology & Oncology · Richmond, VA
- Ajay K. Gopal Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Utah Hospital and Clinics, UT $229,645
- City of Hope National Medical Ctr $187,365
- Mayo Clinic Scottsdale $136,947
- University of Miami $127,577
- Memorial Sloan Kettering Cancer Center $52,085
- Northwestern University $50,044
- Wake Forest University Health Sciences $48,717
- Dana Farber Mass General Brigham Cancer Care Inc $44,940
- The University of Texas Southwestern Med $40,840
- Virginia Commonwealth University $30,865
- University of Maryland Medical Center $24,369
- Medstar Georgetown University Hospital $14,270
- University of Washington Medical Ctr, WA $8,729
- Radmetrix $6,620
- Vx3 Imaging PC $3,310
- $3,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.